Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upamostat - RedHill Biopharma

Drug Profile

Upamostat - RedHill Biopharma

Alternative Names: Mesupron; RHB-107; WX-671

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wilex
  • Developer Heidelberg Pharma AG; Link Health Group; RedHill Biopharma; WILEX AG
  • Class Antineoplastics; Piperazines; Small molecules
  • Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Pancreatic cancer
  • Clinical Phase Unknown Cancer; Gastrointestinal disorders
  • Preclinical Solid tumours
  • Discontinued Head and neck cancer

Most Recent Events

  • 22 Jan 2019 Link Health plans a phase II trial for Cancer in China
  • 31 Dec 2018 The Chinese National Medical Product Administration approves IND application for upamostat in Cancer
  • 01 Aug 2018 Clinical trials in Gastrointestinal disorders (PO) (RedHill Biopharma pipeline, August 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top